GCircular Dichroism Spectrometers - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

Key Highlights

• The COVID-19 pandemic significantly impacted the market initially due to the lockdown restrictions imposed by the countries to control the spread of the virus, thereby impacting research and development activities. But during the late pandemic, very intensive research and development activities were started to find a cure for SARS-CoV-2 virus infection in which circular dichroism spectrometers were also used for the understanding of the molecular structure and chiral activities of biomolecules such as protein and DNA.
• For instance, according to the research study published in June 2021 in NCBI, circular dichroism is a common technique in biochemistry, structural biology, and pharmaceutical chemistry, and it is a widely used method for examining the structures and conformational changes of proteins. Therefore, the outbreak of the pandemic increased research activities, which in turn propelled the demand for circular dichroism spectrometers. Thus, the market witnessed considerable growth during the pandemic. Furthermore, the market has seen a surge post-pandemic due to the increased adoption of circular dichroism spectrophotometers in the development of vaccines for COVID-19.
• The increasing popularity of biologics and increasing investments by private and public sectors in the R&D of biopharmaceuticals are the major factors propelling the market growth. The circular dichroism spectrometers are used in the study of molecular structure and chiral activities of biomolecules, and their use is expected to increase with the growing popularity and usage of biopharmaceuticals or biologics (for example, vaccines, gene and cellular therapies, fusion proteins, insulin, interferon, and monoclonal antibody (mAb) among others) that are used in the treatment of various chronic and rare diseases.
• For instance, according to the April 2022 report of the American Cancer Society, biologics are used in the treatment of cancer in many ways and are being used widely for the treatment. Furthermore, in June 2022, Amgen Inc. received approval for RIABNI (rituximab-Marx), a biosimilar to Rituxan, from the United States Food and Drug Administration for adults with moderate to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies in combination with methotrexate. Hence, the growing usage of biologics drugs and their potential in treating various diseases is expected to increase intensive research and development activities, where circular dichroism spectrometers are used in the analysis of biomolecules, and thus, the demand for circular dichroism spectrometers is expected to increase over the forecast period that is expected to boost growth in the studied market.
• Moreover, the growing research and development activities, along with new investments in the area by the government as well as private entities, are expected to fuel growth in the circular dichroism spectrometers market over the forecast period. For instance, in August 2022, Innovent Biologics of China and Paris-based Sanofi would invest USD 2.42 billion in the biopharma group to jointly develop two cancer drugs in China. As per Innovent Biologics, SAR408701, or tusamitamab ravtansine, would be used to treat lung, gastric, and other cancers, while SAR444245, or non-alpha IL-2, was under phase-II studies for skin cancer, head, and neck tumors, among others.
• In addition, in June 2022, the Rare Disease division of AstraZeneca, Alexion, spent about EUR 65 million (USD 68.6 million) to expand its manufacturing capabilities in Ireland, and over the next 18 months, the investment will be used by the company to build up its biologics manufacturing capacity and increase research and development initiatives in the country. Therefore, due to the above-mentioned factors, the demand for circular dichroism spectrometers is expected to increase; thereby considerable market growth is anticipated over the forecast period.
• Therefore, the rising investments in the development of biologics and biopharmaceuticals, along with the increasing investments by private and public sectors in R&D, are the factors expected to drive the market growth. However, the lack of skilled professionals is expected to restrain the growth of the circular dichroism spectrometers market over the forecast period.

Circular Dichroism Spectrometers Market Trends

Pharmaceutical Industry is Expected to Witness Healthy Growth Over the Forecast Period

• The pharmaceutical industry is one of the largest end-users of various analytical instruments as they are intensively involved in the research and development activities of biologics and other drug molecules; hence, the use of circular dichroism spectrometers is expected to increase among the pharmaceutical companies, and the market is expected to grow.
• For instance, according to the November 2021 report of the Office for National Statistics (ONS) of the United Kingdom, the amount spent on research and development annually in the pharmaceutical industry in the United Kingdom has increased by 6% to an all-time high of GBP 5.02 billion (USD 5.99 billion), which is about 18.6 of the total research and development spending of the United Kingdom.
• Furthermore, the importance of circular dichroism spectrometers in the analytical development of biopharmaceuticals is expected to drive segment growth. For instance, according to the study published by JASCO Corporation, circular dichroism (CD) measurements can provide information regarding changes in protein structure in small quantities of samples. Since protein structure and activity are closely related, CD measurements are widely accepted in the quality control of protein, which includes biomedicines. Such studies propel the segment growth due to increased demand for circular dichroism spectrometers in the pharmaceutical industry.
• Moreover, the growing investment in drug research and development activities by the key market players in the area is further expected to increase the demand for circular dichroism spectrometers, which is expected to boost the segment's growth. For instance, in May 2022, Pfizer Inc. launched a global drug research and development center at the Indian Institute of Technology (IIT) Madras, India, with an investment of about USD 20.0 million. Therefore, due to the aforementioned factors, the pharmaceutical industry is expected to hold a significant share of the studied market over the forecast period.
• Therefore, owing to the above-mentioned factors, considerable segment growth is anticipated over the forecast period.

North America is Expected to Hold a Significant Share in the Circular Dichroism Spectrometers Market Over the Forecast Period

• The pharmaceutical industry is one of the largest end-users of various analytical instruments as they are intensively involved in the research and development activities of biologics and other drug molecules; hence, the use of circular dichroism spectrometers is expected to increase among the pharmaceutical companies, and the market is expected to grow.
• For instance, according to the November 2021 report of the Office for National Statistics (ONS) of the United Kingdom, the amount spent on research and development annually in the pharmaceutical industry in the United Kingdom has increased by 6% to an all-time high of GBP 5.02 billion (USD 5.99 billion), which is about 18.6 of the total research and development spending of the United Kingdom.
• Furthermore, the importance of circular dichroism spectrometers in the analytical development of biopharmaceuticals is expected to drive segment growth. For instance, according to the study published by JASCO Corporation, circular dichroism (CD) measurements can provide information regarding changes in protein structure in small quantities of samples. Since protein structure and activity are closely related, CD measurements are widely accepted in the quality control of protein, which includes biomedicines. Such studies propel the segment growth due to increased demand for circular dichroism spectrometers in the pharmaceutical industry.
• Moreover, the growing investment in drug research and development activities by the key market players in the area is further expected to increase the demand for circular dichroism spectrometers, which is expected to boost the segment's growth. For instance, in May 2022, Pfizer Inc. launched a global drug research and development center at the Indian Institute of Technology (IIT) Madras, India, with an investment of about USD 20.0 million. Therefore, due to the aforementioned factors, the pharmaceutical industry is expected to hold a significant share of the studied market over the forecast period.
• Therefore, owing to the above-mentioned factors, considerable segment growth is anticipated over the forecast period.

Circular Dichroism Spectrometers Industry Overview

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support